Andrew Smith, MD
Glaucoma Specialist · Irvine, CANPI 1215460670
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,521 of the $3,571 with a category attached, or 70.6%. 12 manufacturers reported payments, led by Alcon Research LLC at 29.4% of the total. Reporting peaked in 2023 at $1,578 and has fallen 93.4% since, to $105 in 2025. That places this record below the midpoint for glaucoma specialist clinicians in CA, where the typical reported total is $4,143.
Across 45 payments — averaging $79.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon Research LLC$1K
- Alcon$972
- AbbVie$471
- Glaukos Corporation$382
- NEW World Medical,inc.$207
- Johnson & Johnson Surgical Vision, Inc.$172
- plus $318 from 6 others
What the payments were for
- Consulting fees$1,05029%
- Food & beverage$2,52171%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon Research LLC | 1 | $1,050 |
| Alcon | 20 | $972 |
| AbbVie(2 entities) | 9 | $471 |
| Glaukos Corporation | 5 | $382 |
| NEW World Medical,inc. | 1 | $207 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $172 |
| Sight Sciences, Inc. | 2 | $120 |
| Baxter Healthcare | 1 | $92 |
| Bausch & Lomb Americas Inc. | 1 | $29 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| Thea Pharma Inc. | 1 | $25 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,571 in reported general payments places this provider in the 45th percentile of 64 glaucoma specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RhopressaNetarsudil Mesylate | 125 | $45,250 |
| VyzultaLatanoprostene Bunod | 70 | $23,230 |
| LumiganBimatoprost | 25 | $15,224 |
| Brimonidine Tartrate | 267 | $11,066 |
| RestasisCyclosporine | 13 | $10,644 |
| RocklatanNetarsudil Mesylat/Latanoprost | 17 | $9,512 |
| CombiganBrimonidine Tartrate/Timolol | 27 | $8,000 |
| Alphagan PBrimonidine Tartrate | 18 | $6,604 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 44 | $6,552 |
| Cyclosporine | 12 | $6,420 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 21 | $5,819 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 287 | $5,601 |
| Latanoprost | 457 | $5,049 |
| Prednisolone Acetate | 142 | $3,802 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 23 | $2,724 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $471 | $40,47283 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $29 | $23,23070 claims |
| AlconSimbrinza | $972 | $5,81921 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $24 | $1,62418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 64 glaucoma specialist providers in California.
Other glaucoma specialist in Irvine
- Sameh MosaedIrvine$44K
- Ken LinIrvine$30K
- Austin FoxIrvine$6K
- Jason BacharachPetaluma$1.7M
- Billy PanBeverly Hills$250K
- Jacob BrubakerSacramento$229K
- Felise May BarteSanta Clara$121K
- Houman VosoghiWestlake Village$119K
- Robert ChangStanford$105K
- Sophia WangStanford$77K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.